Valsartan

We help to accelerate the time-to-market of your peptide APIs and formulations Dr. Reddy's peptide unit has decades of experience in process development and production of peptide APIs and formulations. This experience is brought to bear on a comprehensive offering that integrates a continuum of services ...

Dr. Reddy’s has the capabilities and capacities to manufacture and deliver sartan APIs in accordance with global regulations. Our team of experts developed processes and the analytical methods to avoid the presence of nitrosamine impurities, which are already suitable to confirm future requirements of ...

Dr. Reddy’s has the capabilities and capacities to manufacture and deliver Irbesartan APIs in accordance with global regulations. Our team of experts developed processes and the analytical methods to avoid the presence of nitrosamine impurities, which are already suitable to confirm future requirements...

Dr. Reddy’s has the capabilities and capacities to manufacture and deliver Telmisartan in accordance with global regulations. Our team of experts developed processes and the analytical methods to avoid the presence of nitrosamine impurities, which are already suitable to confirm future requirements of ...

High quality APIs to accelerate your generic product launches. Catering to leading innovator and generic companies across the world, Dr. Reddy’s is recognized as one of the largest API suppliers worldwide. The launch of Dr. Reddy’s XCEED – a digital customer service platform - gives customers inst...

Dr. Reddy's Custom Pharma Service offers a complete solution for highly potent and cytotoxic compounds from API development and manufacturing to development and commercial manufacturing of the finished product.

We can support you with an exceptional breadth of capabilities for development a...

Creating high-quality, affordable active pharmaceutical ingredients (APIs) is one of the keys to help us bring good health to all. Our API Business caters to leading innovator and generic companies across the US, Europe, Latin America, Japan, Korea and other emerging markets. Over the years, we have develo...

Dr. Reddy's Custom Pharma Services manufactures outsourced pharmaceutical products in a broad range of dosage forms. Our strategy for success is based on adherence to three principles: outstanding quality; international regulatory compliance; and superior technology transfer capabilities. With ten for...

CPS is one of the leading manufacturers and suppliers of GMP grade Activated mPEGs for the conjugation of proteins, antibody fragments and peptides to improve the stability and pharmo-kinetic properties of biologic drugs. With outstanding GMP capabilities and back integration to high purity mPEG-OH we can ...

Dr. Reddy’s Centre of Excellence for chiral technologies is located in the Chirotech Technology Centre in Cambridge, (UK). With over 20 years of experience using proprietary and non-proprietary chiral technologies to produce single enantiomer compounds, this world-class center is equipped with the infrastr...

Dr. Reddy's Laboratories Ltd. offers a wide range of products which includes Differentiated Formulations. This products division focuses on initiatives to improve patient experience with our products. Better experience results in better compliance, which means better health and outcomes for patients. Conta...

Therapeutic CategoryAnti-Diabetic/ Weight Management

What are APIs? As the name suggests, Active Pharmaceutical Ingredients (APIs) are the heart of any dosage form, whether they are oral, injectable or inhaled, and are absolutely essential to the development of a formulated product.

Sugammadex sodium is one of the key molecules in Dr. Reddy’s API portfolio and an ideal use case on how a thorough understanding of the interaction between API and formulation can significantly improve the robustness of the formulation process considering the drug substance’s proneness to degradation in the formulation process, specifically during the terminal sterilization (TS) process for intravenous injection.

At Dr. Reddy’s, we’re in the business of ensuring good health for both people and the planet. Our experts will share insights on our sustainability approach and on how it helps B2B customers support their sustainable supply chain performance while sourcing APIs. Please register here: 

• We offer polymorphic crystalline form 2.• A novel synthetic process developed for crystalline form 2.• Quality by design (QBD) based API development for a consistent quality profile

World Economic Forum recognises Dr. Reddy’s Hyderabad factory as part of its Global Lighthouse Network • Dr. Reddy’s largest manufacturing facility in Bachupally, Hyderabad, joins Global Lighthouse Network of the World Economic Forum • Journey started four years ago with digitisation of infrastructure and processes. Two years ago, Project ‘OpsNext’ saw deployment of six Industry 4.0 technologies, 40+ business impact linked use cases and heavy investment in people capabilities • Significant business results seen – 43% manufacturing cost improvement, 30% reduction in production lead time, 41% energy consumption reduction, and significant dip in quality deviations • Dr. Reddy’s aspiration is to be the most efficient pharma operations in the world • Efforts key to staying competitive, meeting business imperatives and ESG goals for environmental stewardship (100% renewable energy by 2030, carbon neutrality in direct operations by 2030) and for patients (reaching over 1.5 billion patients by 2030, 25% of launches to be first-to-market by 2027)

Crystalline form-I i.e., Innovator form.• The control strategy for the API impurity prole has been designed through quality-by-design (QbD) based development.• Lactam impurity levels are not detected, thus able to achieve USP/ EP compliance after milling - opening a possibility for a wide range of delivery systems

Dr. Reddy's Laboratories Ltd. announces partnering with FUJIFILM Corporation through FUJIFILM Toyama Chemical Co. Ltd.  and Global Response Aid for the development, manufacture and sales of Avigan® Tablets (generic name: favipiravir), a potential treatment of COVID-19.

The pharma industry is aware that it needs to improve the representation of women and minority communities in its businesses. The benefits of diverse teams are clear, yet it isn’t an easy road. How can companies create an environment where people feel safe, thrive, and attract the best?
Approaching Diversity and Inclusion as part of a wider Sustainability / Environment, Social, and Governance (ESG) performance is an essential indicator of pharma companies' commitment to driving I&D for a more diverse and successful workplace, which ultimately also ensures to better serve patients around the world.

A global pandemic demands a fast response. The research-based pharmaceutical industry is working upstream at extraordinary speed to develop a safe and effective vaccine for COVID19. Pharmaceutical companies around the globe are joining forces and speeding up the process by conducting phases and development in parallel and forging new partnerships and collaboration. The pharmaceutical and life science industry has faced the need to leverage science and technology, developed pre and during the pandemic. Firms are coming up with new ways to maintain production despite disrupted supply chains, or they are mobilizing to design new products as demand for existing products collapses. This discussion will examine how the COVID-19 pandemic is driving pharma and life science companies to collaborate, innovate and prepare for an uncertain future. This webinar was originally aired as part of the CPHI Festival of Pharma.

Dabired is ready to fill Dabigatran Etexilate Mesylate 42.04% w/w pellets which are designed to integrate seamlessly into your encapsulation process.

The pellets are designed to integrate seamlessly into your encapsulation process to. Bio-compliant Dabired, post encapsulation has successfully demonstrated in-vivo bioequivalence. Faster formulation development: Dabired pellets are ready to fill into capsules, and help reduce the steps to formulation development. Process-controlled impurity profile, robust process design and analytical methods ensure well-controlled impurity profiles, including critical amide degradation impurities.

Good Health Can’t Wait. Our belief is rooted in our empathy with our patients and partners. It stems from our deep understanding ofpatient needs, and our determination to meet those needs by resolving challenges that only a few can. Our belief rests on our dynamism in serving the unmet and under met needs with speed and agility. Watch the video to learn more.

This whitepaper outlines Dr. Reddy’s development and characterization approach for the API and how formulation success and early market reach can be facilitated.

Get access to one of the largest portfolios of high-quality APIs and formulations.

Sitagliptin case: Enhancing formulation development and early market access through an integrated understanding of key API attributes.

Learn more about Dr. Reddy's. Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com